AI assistant
Edwards Lifesciences Corp — Director's Dealing 2021
Jun 15, 2021
30042_dirs_2021-06-14_93a5344e-a4d5-4ac2-9af6-7027b6449f69.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Edwards Lifesciences Corp (EW)
CIK: 0001099800
Period of Report: 2021-06-14
Reporting Person: Chopra Daveen (CVP, Surgical Structural Heart)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-14 | Common Stock | M | 24000.0000 | $45.2767 | Acquired | 39827.0000 | Direct |
| 2021-06-14 | Common Stock | S | 24000.0000 | $99.9579 | Disposed | 15827.0000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-14 | Employee Stock Option (Right to Acquire) | $45.2767 | M | 24000.0000 | Disposed | 2025-05-16 | Common Stock (24000.0000) | Direct |
Footnotes
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2021.
F2: This transaction was executed in multiple trades at prices ranging from $99.58 to $100.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.